Follow
Stephen Gately
Stephen Gately
CEO Translational Drug Development
Verified email at td2inc.com
Title
Cited by
Cited by
Year
Combined effects of angiostatin and ionizing radiation in antitumour therapy
HJ Mauceri, NN Hanna, MA Beckett, DH Gorski, MJ Staba, KA Stellato, ...
Nature 394 (6690), 287-291, 1998
8311998
The contributions of cyclooxygenase-2 to tumor angiogenesis
S Gately
Cancer and metastasis reviews 19 (1), 19-27, 2000
5292000
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy
S Gately, WW Li
Seminars in Oncology 31, 2-11, 2004
4742004
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin
S Gately, P Twardowski, MS Stack, DL Cundiff, D Grella, FJ Castellino, ...
Proceedings of the National Academy of Sciences 94 (20), 10868-10872, 1997
3881997
Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin
S Gately, P Twardowski, MS Stack, M Patrick, L Boggio, DL Cundiff, ...
Cancer Research 56 (21), 4887-4890, 1996
2841996
Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor.
SS Brem, D Zagzag, AM Tsanaclis, S Gately, MP Elkouby, SE Brien
The American journal of pathology 137 (5), 1121, 1990
2791990
Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin
DH Gorski, HJ Mauceri, RM Salloum, S Gately, S Hellman, MA Beckett, ...
Cancer research 58 (24), 5686-5689, 1998
2701998
Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and …
GA Soff, J Sanderowitz, S Gately, E Verrusio, I Weiss, S Brem, HC Kwaan
The Journal of clinical investigation 96 (6), 2593-2600, 1995
2001995
Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase …
S Takano, S Gately, ME Neville, WF Herblin, JL Gross, H Engelhard, ...
Cancer research 54 (10), 2654-2660, 1994
1811994
Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation
MS STACK, S GATELY, LM BAFETTI, JJ ENGHILD, GA SOFF
Biochemical Journal 340 (1), 77-84, 1999
1781999
β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites
D Frost, B Meechoovet, T Wang, S Gately, M Giorgetti, I Shcherbakova, ...
Plos one 6 (5), e19264, 2011
1682011
Antiangiogenic scheduling of lower dose cancer chemotherapy.
S Gately, R Kerbel
Cancer journal (Sudbury, Mass.) 7 (5), 427-436, 2001
1652001
Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis
S Gately, R Kerbel
Progress in Experimental Tumor Research 37, 179-192, 2003
1592003
Human Angiostatin Inhibits Murine Hemangioendothelioma Tumor Growth in Vivo
BJ Lannutti, ST Gately, ME Quevedo, GA Soff, AS Paller
Cancer research 57 (23), 5277-5280, 1997
1401997
Immunolocalization of basic fibroblast growth factor to the micro vasculature of human brain tumors
S Brem, AMC Tsanaclis, S Gately, JL Gross, WF Herblin
Cancer 70 (11), 2673-2680, 1992
1361992
Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds
S Gately, R West
Drug Development Research 68 (4), 156-163, 2007
1332007
Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP.
GA Soff, TL Cornwell, DL Cundiff, S Gately, TM Lincoln
The Journal of clinical investigation 100 (10), 2580-2587, 1997
1231997
Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
ML Goodall, T Wang, KR Martin, MG Kortus, AL Kauffman, JM Trent, ...
Autophagy 10 (6), 1120-1136, 2014
932014
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP McKearn, G Gordon, JJ Cunningham, ST Gately, AT Koki, JL Masferrer
US Patent 6,858,598, 2005
702005
Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent
JP McKearn, G Gordon, JJ Cunningham, ST Gately, AT Koki, JL Masferrer
US Patent 6,916,800, 2005
562005
The system can't perform the operation now. Try again later.
Articles 1–20